EUDA Health Holdings Limited (NASDAQ:EUDA) Sees Significant Increase in Short Interest

by · The Cerbat Gem

EUDA Health Holdings Limited (NASDAQ:EUDAGet Free Report) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 87,001 shares, an increase of 1,736.6% from the April 15th total of 4,737 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average daily trading volume, of 574,255 shares, the days-to-cover ratio is presently 0.2 days.

EUDA Health Price Performance

Shares of NASDAQ EUDA traded up $0.64 during midday trading on Monday, hitting $14.40. The company’s stock had a trading volume of 13,447 shares, compared to its average volume of 344,706. The business’s fifty day simple moving average is $10.50 and its two-hundred day simple moving average is $30.94. EUDA Health has a 1 year low of $5.26 and a 1 year high of $86.00. The firm has a market capitalization of $36.29 million, a price-to-earnings ratio of -6.00 and a beta of 0.56.

EUDA Health (NASDAQ:EUDAGet Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.76. The business had revenue of $1.92 million during the quarter, compared to analysts’ expectations of $3.90 million. Analysts anticipate that EUDA Health will post 1.6 EPS for the current fiscal year.

Analysts Set New Price Targets

EUDA has been the subject of several research analyst reports. Zacks Research lowered shares of EUDA Health from a “hold” rating to a “strong sell” rating in a research note on Monday, March 23rd. Greenridge Global lowered their target price on shares of EUDA Health from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Finally, Weiss Ratings lowered shares of EUDA Health from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, EUDA Health has a consensus rating of “Reduce” and a consensus target price of $55.00.

Get Our Latest Research Report on EUDA

Institutional Inflows and Outflows

An institutional investor recently bought a new position in EUDA Health stock. Jane Street Group LLC acquired a new stake in EUDA Health Holdings Limited (NASDAQ:EUDAFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 25,675 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.07% of EUDA Health as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 4.35% of the company’s stock.

EUDA Health Company Profile

(Get Free Report)

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.

Read More